Cost-effectiveness of drug-eluting stents: Implications for clinical practice and healthcare costs;Coste-efectividad de los stents liberadores de fármacos: Implicaciones para la práctica clĺinica y el coste sanitario

Revista Espanola de Cardiologia

Volumn 59, Issue 9, 2006, Pages 865-868

  Oliva, Gloria ^a  

^a Catalan Agency for Health Technology Assessment and Research   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 578; PACLITAXEL; RAPAMYCIN; TSUKUBAENOLIDE;

CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG ELUTING STENT; ECONOMIC EVALUATION; EDITORIAL; HEALTH CARE COST; HUMAN; IN-STENT RESTENOSIS; SURGICAL MORTALITY; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 33751016674     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13093251     Document Type: Editorial

References (18)

1. Regar E, Serruys PW. El estudio RAVEL. Reestenosis del cero por ciento: ¡un sueño del cardiólogo hecho realidad! [editorial]. Rev Esp Cardiol. 2002;55:459-62.
2. López-Palop R, Moreu J, Fernández-Vazquez F, Hernández R. Registro Español de Hemodinámica y Cardiología Intervencionista XIV Informe Oficial de la Sección de Hemodinámica y Cardiología Intervencionista de la Sociedad Española de Cardiología (1990-2004). Rev Esp Cardiol. 2005;58:1318-34.
3. Hernández RA, Fernández F, Moreu J, López R. Cardiología intervencionista 2005. Rev Esp Cardiol. 2006;59 Supl 1:38-49.
4. Moreno R. Stents recubiertos y otros dispositivos antirreestenosis. Orthod Craniofac Res. 2005;58:842-62.
5. Van Domburg RT, Lemos PA, Takkenberg JJ, Liu TK, Van Herwerden LA, Arampatzis CA, et al. The impact of the introduction of drug-eluting stents on the clinical practice of surgical and percutaneous treatment of coronary artery disease. Eur Heart J. 2005;26:675-81.
6. Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C, et al. En representación del Grupo de Trabajo de la Sociedad Europea de Cardiologia de intervención coronaria percutánea. Guías de Práctica Clínica sobre intervencionismo coronario percutáneo. Rev Esp Cardiol. 2005; 58:679-728.
7. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet. 2004;364:583-91.
8. García-Altés A. Twenty years of health care economic analysis in Spain: are we doing well? Health Econ. 2001;10:715-29.
9. Russell S, Antoñanzas F, Mainar V. Impacto económico del stent coronario Taxus: implicaciones para el sistema sanitario español. Rev Esp Cardiol. 2006;59:889-96.
10. Oliva G, Espallargues M, Pons JMV. Stents recubiertos de fármacos antiproliferativos: revisión sistemática del beneficio y estimación del impacto presupuestario. Rev Esp Cardiol. 2004;57:617-28.
11. Shrive FM, Manns BJ, Galbraith PD, Knudtson ML, Ghali WA. Economic evaluation of sirolimus-eluting stents. CMAJ. 2005;172:345-51.
12. Brophy JM, Erickson LJ. Cost-effectiveness of drug-eluting coronary stents in Quebec, Canada. Int J Technol Assess Health Care. 2005;21:326-33.
13. Mittmann N, Brown A, Seung SJ, Coyle D, Cohen E, Brophy J, et al. Economic evaluation of drug eluting stents. Technology report no. 53. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2005.
14. Lord SJ, Howard K, Allen F, Marinovich L, Burgess DC, King R, et al. A systematic review and economic analysis of drug-eluting coronary stents available in Australia. Med J Aust. 2005;183:464-71.
15. Cohen DJ, Bakhai A, Shi C, Githiora L, Lavelle T, Berezin RH, et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation. 2004;110:508-14.
16. Bagust A, Grayson AD, Palmer ND, Perry RA, Walley T. Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study. Heart. 2006;92:68-74.
17. Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet. 2005;366:921-9.
18. Ekman M, Sjögren I, James S. Cost-effectiveness of the Taxus paclitaxel-eluting stent in the Swedish healthcare system. Scand Cardiovasc J. 2006;40:17-24.